Introduction
There are two completely different ways to think about your Lp(a) number.
The first way is the conventional approach: Lp(a) is a risk factor. It is genetically determined. It causes heart attacks. Something must be done to lower it. Drugs are developed. Statins are prescribed. PCSK9 inhibitors are added. The number drops by a percentage. The doctor is satisfied. The guidelines are followed.
The second way is the root-cause approach: Lp(a) is not a random genetic error. It is a repair particle produced by your liver in response to structural weakness in your artery walls. When your arteries lack the nutrients they need to stay strong—specifically, vitamin C, lysine, and proline—collagen weakens. Cracks develop. Your body deploys Lp(a) to patch the damage. The goal is not simply to lower a number. The goal is to normalize the process so your body no longer needs to overproduce Lp(a) in the first place.
One approach uses a blockade. The other provides building blocks.
One manages a marker. The other restores function.
This article explains the difference—and why it matters for your heart.
The Conventional Approach: Blocking a Pathway to Lower a Number
When conventional medicine identifies an elevated biomarker, its instinct is to find a drug that suppresses it. This approach has been remarkably successful for LDL cholesterol. Statins block HMG-CoA reductase, an enzyme the liver uses to produce cholesterol. LDL levels drop. Cardiovascular risk decreases.
But Lp(a) has proven stubbornly resistant to this strategy.
Statins, the workhorse of lipid management, do not lower Lp(a). Some studies suggest they may modestly increase it by 10–20% . This is a significant limitation, given that elevated Lp(a) is now recognized as an independent, causal risk factor for cardiovascular disease .
Niacin can lower Lp(a) by about 23% at high doses, but its use is limited by side effects—flushing, hepatotoxicity, and new-onset diabetes—and a lack of outcomes evidence .
PCSK9 inhibitors have emerged as the most promising pharmacologic option. They lower Lp(a) by approximately 20–30%. But as we discussed in the previous article, this reduction is modest and the mechanism remains unclear .
Newer therapies are in development. Pelacarsen, an antisense oligonucleotide, specifically targets Lp(a) production and can reduce levels by up to 80%. It is currently in Phase III trials . Olpasiran, a small interfering RNA, has shown reductions exceeding 95% . These drugs are exciting, but they are still years away from approval, and their long-term safety profile is unknown.
The common thread in all these approaches is the underlying philosophy: find a molecule to block, inhibit, or interfere with the production of Lp(a). The goal is a lower number on a lab report.
The Root-Cause Approach: Providing Building Blocks to Restore Function
The root-cause approach starts with a completely different question: Why is your body producing so much Lp(a)?
Lp(a) is not a metabolic accident. It is a lipoprotein with a specific, evolutionarily conserved function. Lp(a) is structurally similar to plasminogen, a protein involved in clotting and wound healing . It has lysine-binding sites that allow it to adhere to damaged tissue . It carries cholesterol to sites of injury. In multiple studies, Lp(a) has been shown to promote wound healing and tissue repair .
In other words, Lp(a) is a biological band-aid.
Why would your liver produce more of it? Because there is more damage to repair.
Your artery walls are constantly subjected to mechanical stress—the pressure of blood flow, the stretching and contracting of the vessel with every heartbeat. To withstand this stress, the artery wall is built from collagen, a tough, flexible protein that gives the vessel its structural integrity.
Collagen synthesis depends absolutely on vitamin C. Vitamin C is the essential co-factor for the enzymes prolyl hydroxylase and lysyl hydroxylase, which stabilize and cross-link collagen fibres . Without adequate vitamin C, collagen cannot form properly. The artery wall becomes weak. Microscopic cracks develop in the endothelial lining.
This is where Lp(a) enters the picture.
When the artery wall develops cracks, the body responds as it would to any wound: it sends repair material to the site. Lp(a) particles travel to the damaged area and deposit their cholesterol and apolipoprotein(a) content to patch the crack. Over decades, layer upon layer of these patches builds up into what we call atherosclerotic plaque.
A 1990 US patent, based on the work of Linus Pauling and Matthias Rath, proved this directly. Using gel electrophoresis, they showed that the primary component of human arterial plaque is Lp(a)—not ordinary LDL cholesterol.
The sequence is clear: Vitamin C deficiency → collagen weakness → micro-cracks → Lp(a) repair → plaque accumulation.
Your Lp(a) is not high because your body is betraying you. It is high because your body is trying to save you—by patching arteries that have become too weak to hold themselves together.
Why Building Blocks Work Better Than Blockades
If Lp(a) is a repair particle, then the logical solution is not to block its production. The logical solution is to reduce the need for repair.
How? By providing the nutrients your artery walls need to build strong, healthy collagen in the first place.
Vitamin C is the master builder. It activates the enzymes that knit amino acids into strong collagen fibres. Without it, collagen synthesis stalls. With it, the artery wall can repair itself continuously.
L-Lysine is an essential amino acid. It forms the cross-links that give collagen its tensile strength. Equally important, lysine can occupy the same binding sites on the artery wall where Lp(a) tries to attach. By occupying those sites, lysine acts as a natural shield, preventing Lp(a) from depositing while the artery repairs itself .
L-Proline is the second major structural amino acid in collagen. Together with lysine, it provides the actual building material for new, strong collagen fibres.
When these three nutrients—vitamin C, lysine, and proline—are provided in adequate amounts, a cascade of repair begins:
- Collagen synthesis is reactivated.
- The artery wall regains its strength and flexibility.
- Micro-cracks begin to heal.
- The signal to produce excess Lp(a) diminishes.
- New Lp(a) deposition slows or stops.
- Over time, existing plaque may be resorbed as the structural integrity of the vessel is restored.
This is not a blockade. It is a restoration of function. The body is given what it needs to do what it was designed to do.
The Difference in One Table
| Aspect | Pharmacologic Approach (Lowering) | Root-Cause Approach (Normalizing) |
| Goal | Reduce a number on a lab report | Restore normal cellular function |
| Mechanism | Block an enzyme or inhibit gene expression | Provide essential nutrients for collagen synthesis |
| Effect on Lp(a) | Lowers by 20–80% (depending on drug) | May normalize over time as arterial repair reduces the need for Lp(a) |
| Effect on Arteries | None directly—plaque may stabilize but structural weakness is not addressed | Strengthens the collagen matrix, heals micro-cracks, restores vessel integrity |
| Side Effects | Injection site reactions, flu-like symptoms, potential long-term unknowns with newer drugs | No known side effects when nutrients are used at appropriate doses |
| Cost | Thousands of dollars per year for PCSK9 inhibitors | A fraction of the cost |
| Philosophy | Manage a disease | Support health |
My Own Experience: Normalization, Not Suppression
I did not set out to challenge conventional cardiology. I was forced to find answers when my own heart failed.
In 2010, I was diagnosed with two coronary artery blockages above 80%. Bypass surgery was recommended. As a PhD medicinal chemist trained at the Central Drug Research Institute, I had the skills to investigate why my arteries had failed.
What I discovered—the Lp(a)–vitamin C connection, the collagen repair mechanism—changed my life. I formulated a protocol based on vitamin C, lysine, and proline. I provided my arteries with the building blocks they had been missing.
I did not take a PCSK9 inhibitor. I did not block any enzyme. I did not interfere with any gene. I simply gave my body what it needed to repair itself.
Today, at 75, I am medicine-free. My heart functions well. I am not a special case. I am someone who chose normalization over suppression.
My book, Reverse Heart Disease: No Lifelong Suffering, contains the full protocol—what I took, why I took it, and how you can do the same.
The Choice Before You
You have been told your Lp(a) is high. You are searching for what to do.
You now have a choice.
You can follow the conventional path. You can take statins to lower your LDL, even though they do not lower Lp(a). You can add a PCSK9 inhibitor and accept a 20–30% reduction in Lp(a) as the best that medicine can offer. You can wait for the new RNA-based drugs to come to market, with their unknown long-term safety profiles and their significant cost. You can manage your numbers and hope for the best.
Or you can take a different path.
You can understand why your Lp(a) is elevated in the first place. You can recognize Lp(a) for what it is: a repair particle your body produces because your arteries need repair. You can provide the nutrients your arteries have been missing—vitamin C to activate collagen synthesis, lysine and proline to supply the building blocks. You can normalize the process, not just suppress the marker.
One path manages a disease. The other supports health.
My book is for those who choose the second path.
Dr. Balaram Dhotre is a PhD medicinal chemist, cellular nutritionist, and the author of Unraveling the Root Cause of Chronic Diseases and Reverse Heart Disease: No Lifelong Suffering. He writes at lyproc.com to help people understand the true root cause of chronic illness and reclaim their health.
[Click here to get your copy of Reverse Heart Disease: No Lifelong Suffering on Amazon]
——————————————————————————————————————————-
My Books
———————————————————————————————————————————–
Links on Amazon
Unraveling The Root Cause of Chronic Diseases:
Reverse Heart Disease: No Lifelong Suffering
————————————————————————————————————————-